Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
For the year, the company expects net product sales from continuing operations to be approximately $128 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.31 USD | -4.39% | +0.72% | -29.87% |
1st Jan change | Capi. | |
---|---|---|
-29.87% | 502M | |
+4.01% | 108B | |
+11.03% | 104B | |
+1.28% | 22.33B | |
-13.22% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.60% | 17.64B | |
+3.78% | 14.05B | |
+36.73% | 12.51B |